Oncology at Huadong Hospital Shanghai | CMCS

Expert Cancer Care with a Geriatric Oncology Focus at One of Shanghai's Most Prestigious Hospitals

The Department of Oncology at Huadong Hospital — affiliated with Fudan University — is one of Shanghai's most distinguished oncology centers, with a national reputation for excellence in medical oncology, geriatric oncology, cancer nutrition support, palliative care, and the management of complex cancer conditions in older adults. As one of Shanghai's most prestigious hospitals with a long tradition of serving senior patients, Huadong Hospital's oncology department offers a unique and nationally recognized expertise in geriatric oncology — the specialized management of cancer in older adults with frailty, multiple comorbidities, and complex functional needs — uniquely integrated with the hospital's world-class geriatric medicine and clinical nutrition programs. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their cancer care journey at Huadong Hospital.

About the Department

The oncology department is a national key clinical specialty operating dedicated oncology inpatient wards, a comprehensive outpatient oncology clinic, a chemotherapy day unit, a geriatric oncology clinic, a cancer nutrition support clinic, a palliative care program, a clinical trials unit, and works in close collaboration with geriatric medicine, clinical nutrition, radiation oncology, surgery, and palliative care through a fully integrated multidisciplinary tumor board.

Geriatric Oncology

Huadong Hospital's geriatric oncology program is one of China's most specialized and nationally recognized, addressing the unique needs of older cancer patients:

• Geriatric Oncology Assessment (GOA) — Comprehensive geriatric assessment adapted for cancer patients; G8 screening tool; VES-13; functional status (ADL, IADL); cognitive assessment; nutritional assessment (MNA); comorbidity burden (CIRS-G); polypharmacy review; social support; falls risk; frailty phenotype
• Treatment Decision-Making in Older Adults — Frailty-adjusted treatment intensity; fit vs. vulnerable vs. frail patient stratification; shared decision-making; goals-of-care discussion; life expectancy estimation; treatment toxicity prediction (CARG toxicity score; CRASH score)
• Chemotherapy in Older Adults — Dose modification for frailty and organ function; G-CSF prophylaxis; antiemetic optimization; toxicity monitoring; dose-dense vs. standard schedules; oral chemotherapy preference for frail patients
• Immunotherapy in Older Adults — PD-1/PD-L1 inhibitors in elderly patients; immune-related adverse event (irAE) management; checkpoint inhibitor-associated myocarditis; colitis; pneumonitis; endocrinopathies
• Targeted Therapy in Older Adults — Oral targeted agents preferred for frail patients; drug-drug interaction assessment; polypharmacy management; dose modification
• Prehabilitation for Older Cancer Patients — Pre-operative exercise; nutritional optimization; psychological preparation; coordination with clinical nutrition and rehabilitation

Lung Cancer

• Non-Small Cell Lung Cancer (NSCLC) — Comprehensive molecular profiling (EGFR, ALK, ROS1, KRAS G12C, MET exon 14, BRAF V600E, RET, NTRK, HER2); osimertinib for EGFR-mutated NSCLC; alectinib, brigatinib, lorlatinib for ALK-positive; sotorasib, adagrasib for KRAS G12C; tepotinib, capmatinib for MET exon 14; selpercatinib for RET; entrectinib, larotrectinib for NTRK; pembrolizumab + chemotherapy; nivolumab + ipilimumab; atezolizumab; durvalumab for stage III
• Small Cell Lung Cancer (SCLC) — Atezolizumab + carboplatin + etoposide; durvalumab + chemotherapy; tarlatamab (DLL3-targeted BiTE) for relapsed SCLC; prophylactic cranial irradiation coordination
• Lung Cancer in Older Adults — Frailty-adjusted treatment; oral targeted therapy preferred for EGFR-mutated elderly patients; single-agent chemotherapy for frail patients; palliative care integration

Gastrointestinal Cancers

• Colorectal Cancer — FOLFOX; FOLFIRI; FOLFOXIRI; bevacizumab; cetuximab and panitumumab for RAS/BRAF wild-type; encorafenib + cetuximab for BRAF V600E; pembrolizumab for MSI-H/dMMR; nivolumab + ipilimumab for MSI-H; fruquintinib; trifluridine/tipiracil (TAS-102); regorafenib
• Gastric & Gastroesophageal Junction Cancer — FLOT perioperative chemotherapy; nivolumab + chemotherapy (CheckMate 649); pembrolizumab + chemotherapy (KEYNOTE-590); trastuzumab for HER2-positive; trastuzumab deruxtecan (T-DXd) for HER2-low; zolbetuximab for CLDN18.2-positive
• Hepatocellular Carcinoma (HCC) — Atezolizumab + bevacizumab (IMbrave150); sintilimab + bevacizumab; durvalumab + tremelimumab (HIMALAYA); lenvatinib; sorafenib; TACE coordination; TARE/Y-90 coordination; hepatic resection and transplantation coordination
• Pancreatic Cancer — FOLFIRINOX; gemcitabine + nab-paclitaxel; olaparib for BRCA-mutated; pembrolizumab for MSI-H; NALIRIFOX; eryaspase; coordination with interventional radiology for TACE and IRE
• Cholangiocarcinoma — Gemcitabine + cisplatin + durvalumab (TOPAZ-1); pemigatinib, infigratinib, futibatinib for FGFR2 fusion; ivosidenib for IDH1-mutated; zanidatamab for HER2-amplified

Breast Cancer

• HR+/HER2- Breast Cancer — CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) + aromatase inhibitor or fulvestrant; elacestrant for ESR1-mutated; capivasertib + fulvestrant for PIK3CA/AKT1/PTEN-altered; inavolisib + palbociclib + fulvestrant; olaparib/talazoparib for BRCA-mutated
• HER2+ Breast Cancer — Trastuzumab + pertuzumab + docetaxel (CLEOPATRA); T-DM1; trastuzumab deruxtecan (T-DXd — DESTINY-Breast03); tucatinib + trastuzumab + capecitabine; neratinib; margetuximab
• Triple-Negative Breast Cancer — Pembrolizumab + chemotherapy (KEYNOTE-522); atezolizumab + nab-paclitaxel; sacituzumab govitecan (Trodelvy); olaparib/talazoparib for BRCA-mutated; datopotamab deruxtecan
• Breast Cancer in Older Adults — Frailty-adjusted treatment; oral CDK4/6 inhibitors preferred for frail elderly; endocrine therapy alone for very frail patients; bone health management (denosumab, zoledronic acid)

Hematological Malignancies

• Diffuse Large B-Cell Lymphoma (DLBCL) — R-CHOP; polatuzumab vedotin + R-CHP (pola-R-CHP); CAR-T cell therapy (axicabtagene ciloleucel, lisocabtagene maraleucel) for relapsed/refractory; loncastuximab tesirine; epcoritamab; glofitamab
• Chronic Lymphocytic Leukemia (CLL) — Ibrutinib; acalabrutinib; zanubrutinib; venetoclax + obinutuzumab; venetoclax + ibrutinib; pirtobrutinib for BTK-inhibitor resistant CLL
• Multiple Myeloma — Daratumumab + VRd; isatuximab + VRd; carfilzomib; pomalidomide; elotuzumab; selinexor; belantamab mafodotin; teclistamab; talquetamab; ciltacabtagene autoleucel; idecabtagene vicleucel
• Hematological Malignancies in Older Adults — Frailty-adjusted treatment; venetoclax-based regimens preferred for frail CLL; reduced-intensity conditioning for transplant; geriatric assessment before CAR-T

Cancer Nutrition & Supportive Care

Huadong Hospital's cancer supportive care program is uniquely strengthened by its integration with China's premier clinical nutrition department:

• Cancer Cachexia Management — Anamorelin; megestrol acetate; omega-3 fatty acids; high-protein diet; resistance exercise; coordination with clinical nutrition
• Chemotherapy Toxicity Management — GCSF; antiemetics (ondansetron, aprepitant, olanzapine); mucositis prevention (glutamine, cryotherapy); peripheral neuropathy management; hand-foot syndrome
• Bone Health — Denosumab; zoledronic acid for bone metastases; osteoporosis prevention in cancer survivors
• Palliative Care — Early palliative care integration; pain management; dyspnea; nausea; fatigue; psychological support; goals-of-care; advance care planning; coordination with geriatric medicine

Why International Patients Choose Huadong Hospital Oncology

• Geriatric Oncology Leadership — One of China's most specialized geriatric oncology programs; GOA-guided treatment decisions; frailty-adjusted cancer care
• Nutrition Integration — Unique seamless integration with China's premier clinical nutrition department for cancer cachexia and peri-operative nutrition
• Tarlatamab for SCLC — DLL3-targeted BiTE for relapsed small cell lung cancer
• Zolbetuximab for Gastric Cancer — CLDN18.2-targeted therapy for gastric and GEJ cancer
• Bispecific Antibodies for Lymphoma/Myeloma — Epcoritamab; glofitamab; teclistamab; talquetamab
• Cost-Effectiveness — World-class oncology care at significantly lower cost than equivalent treatment in Western countries

The CMCS Patient Journey

1. Initial Inquiry — Share your cancer diagnosis, pathology reports, molecular profiling results, imaging, and prior treatment history with CMCS.
2. Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
3. Specialist Matching — We identify the most appropriate oncologist based on your cancer type and age — lung, GI, breast, hematological, or geriatric oncology.
4. MDT Submission — We facilitate pre-arrival case review by the multidisciplinary tumor board.
5. Priority Scheduling — We secure a consultation with minimal waiting time.
6. Travel & Logistics — Assistance with visa invitation letters, accessible accommodation near Huadong Hospital, and Shanghai airport transfers.
7. Treatment Coordination — Full coordination of chemotherapy, immunotherapy, targeted therapy, and supportive care scheduling.
8. Post-Treatment Follow-Up — Treatment report translation, response assessment coordination, and remote follow-up after you return home.

Book a Consultation

If you have lung cancer, gastrointestinal cancer, breast cancer, a hematological malignancy, or any cancer — particularly if you are an older adult requiring geriatric oncology expertise — CMCS can arrange a specialist consultation with Huadong Hospital's oncology team in Shanghai.

📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com